The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development

İ. Uçar1, T. Ertekin2, M. Nisari2, D. Ceylan3, Ö. Al2, H. Ülger2

1Department of Physical Therapy and Rehabilitation, Ahi Evran University, Kirsehir, Turkey
2Department of Anatomy, University of Erciyes, Kayseri, Turkey
3Genome and Stem Cell Center, University of Erciyes, Kayseri, Turkey

[Received: 30 July 2015; Accepted: 27 October 2015]

Background: Interferon beta (IFNβ) was the first proven drug for the treatment of multiple sclerosis (MS). The diagnosis of MS frequently occurs in women at childbearing age (especially in twenties and thirties). Therefore, the pregnancy process is major concern for many women with MS. Data on women exposed to IFNβ during pregnancy are limited. The aim of our study was to investigate the teratogenic potential of IFNβ on embryonic development via embryo culture technique. Recently, this technique has been often used for determining teratogenic effect of pharmacologic drugs and potential teratogens on embryonic development.

Materials and methods: In this study, IFNβ was applied to the culture medium and after 48 h of culture effects of IFNβ (1000 IU/IFNβ-1a and 1000 IU/IFNβ-1b) on embryonic development were morphologically investigated.

Results: According to morphologic scoring system, total morphologic score, somite number and protein contents were similar between control group and two experimental groups (p > 0.05). On the other hand, yolk sac diameter, crown-rump length and head length were significantly decreased in two experimental groups compared with control group (p < 0.05).

Conclusions: Consequently, IFNβ-1a and IFNβ-1b, applied to the culture medium, have no macroscopic teratogenic effect on embryonic development. However, in respect of morphometric measurements, IFNβ-1a and IFNβ-1b have caused growth retardation in embryo. This research related to interferon was the first study using vitro embryo culture technique; thus, in our point of view, future studies which will be performed by using different doses of IFN will contribute to the literature. (Folia Morphol 2016; 75, 2: 257–263)

Key words: interferon β-1a, interferon β-1b, whole rat embryo culture

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating, inflammatory, neurodegenerative and neuroimmune disorder that affects white matter of central nervous system [16]. MS is the most common neurologic disease among young adults, typically starting in the third and fourth decades of life. Women are more frequently affected than men [6, 46]. Recent epidemiological studies have demonstrated that the ratio of female/male is gradually increasing worldwide. Thus, MS especially affects women at childbearing age [13, 35, 37]. The status of the embryo affected by the disease, the manner of drug treatment and uncertainties regarding the mechanisms of drug action
in the process of childbirth and breastfeeding made the pregnant women with MS anxious. Pregnancy has no adverse effects on the course of MS [9, 34, 44]. According to the current literature, it has not been determined whether an increase in miscarriage, stillbirth, malformations and birth complications is related to MS [34, 39].

Interferon beta-1b (IFNβ-1b, Betaseron/Betaseron) was the first drug approved for the treatment of MS by Food and Drug Administration (FDA) in 1993 [21, 22, 43]. Later, interferon beta-1a (IFNβ-1a, Avonex/Rebif) was approved for the treatment of Relapsing-Remitting Multiple Sclerosis. IFNβ also received approval to treat Secondary Progressive Multiple Sclerosis in some countries [25]. Interferon (IFN) was discovered accidentally by Alick Isaacs and Jean Lindenmann in 1957 [20]. IFNs are located within the family of glycoproteins known as cytokines. They are water-soluble and endogenous substances, with molecular weight of 17–25 kilodaltons (kDa). IFNs are produced naturally by the several cells such as erythrocytes, fibroblasts, epithelial cells and natural killer cells, in response to bacteria, viruses, parasites and tumour cells. IFNs have a very wide antiviral spectrum [24].

A vast number of different IFN molecules were detected in human cells. IFNs were classified among three classes: type I IFN, type II IFN, and type III IFN. The mammalian type I IFNs are designated IFN-α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon), IFN-τ (tau), IFN-ω (omega), and IFN-ζ (zeta, also known as limitin) [15]. A mature IFNβ protein was composed of 145 amino acids [5]. IFNβ has two subtypes namely IFNβ-1a and IFNβ-1b. Recently, both interferons have a common use in clinics [10]. IFNs were reported to have antiviral, antiproliferative, immunomodulatory and anti-apoptotic activity [21]. Besides, they have effects on the regulation of cell growth and differentiation [41].

Experimental and clinical studies have revealed that IFNβ decreased the progression of MS by reducing relapse rate, frequency and inflammatory indicators on magnetic resonance imaging (MRI) [27]. However, the mechanism of IFNβ action in the treatment of MS has not been elucidated yet [26]. Recently, studies have focused on the immunomodulatory and antiproliferative effects of IFNβ [41]. For the women at childbearing age with MS, it is important to decide to have a planned pregnancy. Otherwise, they will continue to use their medications during pregnancy which may negatively affect the health of the embryo. In terms of a planned pregnancy, the physicians recommend to quit the prescribed medication 3 months before conception [8, 12].

Several studies showed that using IFNβ during the first 3 months of pregnancy increased the risk of stillbirth and low birth weight [2, 4]. However, there are limited studies investigating their teratogenic effects during pregnancy, thus IFNβ-1a, IFNβ-1b have received category C by FDA [12].

The in vitro culture technique was described by New and Stein in 1964 [42]. Recently, this method has been commonly used to determine the effects of pharmacological agents, hormones, chemical and physical factors on the embryonic development and to determine potential teratogens [30]. The in vitro culture of post-implantation rat embryos during the early organogenesis period (from 9.5 to 11.5 pregnancy days) makes it possible to determine risk of teratogenicity in homologous serum [11]. The present study was performed to clarify the in vitro effects of IFNβ-1a and IFNβ-1b on embryonic development during the organogenesis period in the rat.

**MATERIALS AND METHODS**

This study was approved by the Experimental Animals Ethics Committee of Erciyes University, Turkey (The Ethics Committee Number: 12/101). Wistar rats were used and obtained from the Clinical and Experimental Research Centre, Medical Faculty of Erciyes University. The female rats (approximately 8 weeks of age and weighing 150–250 g) were kept in cages as three groups. The males of the same strain were housed singly in mating cages. Male and female rats were placed together in the evening (one pair per cage), and the presence of a vaginal plug the following morning was taken to indicate mating had occurred.

On the assumption that mating occurred around mid-night, the female was considered to be 0.5 day pregnant at noon in the following day. The pregnant rats were sacrificed by overdose ether at 9.5 days of gestation, between 9 a.m. and 10 a.m. in the morning and the embryos were removed from the mother by the procedure described by New [28]. We used 3 dams for each group (totally 9 dams). Using a dissection microscope, the decidua mass was split to expose the conceptus, which was gently teased free and immediately immersed in Hank’s balanced salt solution. The damaged and underdeveloped embryos were discarded. There were 4 to 5 embryos in each bottle which contained 1 mL of immediately centri-
fuged, heat inactivated whole rat serum (WRS) per embryo and these embryos were randomised from several rats.

In order to assess the effect of the IFNβ-1a (Avonex) and IFNβ-1b (Betaferon) on total embryonic growth, embryos were divided into three groups (10 embryos in control group and 9 embryos per two experimental groups). The control group embryos were cultured in WRS. The administration dosages of IFNβ-1a and IFNβ-1b were determined according to the data from previous cell culture studies [47]. For the experimental groups, 1000 IU IFNβ-1a and 1000 IU IFNβ-1b were added to WRS. After 48 h culture period, the embryos from each group were examined under the dissecting microscope and assessed according to the morphological scoring system which takes account of the growth and differentiation of different embryological features, including the appearance of yolk sac circulation, allantois, body flexion, heart, caudal neural tube, hindbrain, midbrain, forebrain, otic system, optic system, olfactory system, branchial arches (bars), maxillary processes, mandibular processes, forelimbs, hindlimbs and somite number [29]. Mean yolk sac diameter, crown-rump length and head lengths were also measured by using ImageJ program (http://rsb.info.nih.gov/ij/docs/index.html). Additionally, protein contents of embryos were determined with using Folin Phenol reagents for all groups [11].

**Statistical analysis**

Data of the morphological score and somite number, yolk sac diameter, crown-rump length and head length were statistically analysed. All data sets were subjected to normality test by the Shapiro-Wilk test. Comparison between the groups was performed by the one way analysis of variance (ANOVA; multiple comparisons were carried out with Tukey Test). Statistical significance was set at p < 0.05. All analyses were performed with the statistical package for scientist (SIGMASTAT) Windows version 3.10.

**RESULTS**

The results of the present study revealed the development of the control group embryos were normal and morphological scoring results were close to the development of an 11.5-day in vivo embryo (Fig. 1). The embryos cultured in IFNβ-1a and IFNβ-1b showed that there was no significant difference in total morphological score, somite number and embryo protein content compared with embryos grown only in WRS (p > 0.05) (Fig. 1). However, when compared with control group, a significant retardation in yolk sac diameter, crown rump length and head length parameters in two experimental groups was determined (p < 0.05). Related results are given in Table 1.

Parameters related to the nervous system were also considered (Table 2). In the experimental groups, the number of embryos that had growth retardation in parameters related to nervous system (caudal neural tube, hindbrain, midbrain, forebrain and olfactory system) were larger compared with the control group. This numerical excess was not statistically significant; however, most of the embryos exposed to IFNβ-1a and IFNβ-1b had open posterior neural tubes, anterior neuropores and poor neural system development (Fig. 1).

**DISCUSSION**

Various disease-modifying drugs, including IFNβ-1a and IFNβ-1b, glatiramer acetate, natalizumab, mitoxantrone, and fingolimod that are licensed worldwide to reduce the frequency of clinical attacks with the expectation of slowing disability progression [14].
Great majority of studies related to IFNs have been
directed towards determination of their effects
on diseases and biological structures [9, 39]. At pres-
ent, recommendation to quit the use of IFN\(\beta\) during
pregnancy is based on findings from animal studies;
in primates, administration of up to 100 times the
recommended weekly human dose of IFN\(\beta\) (based
upon a body surface area comparison) was not asso-
ciated with teratogenicity or adverse effects on foetal
development [18]. In spite of these data, the FDA
has given IFN\(\beta\) drugs a pregnancy category C rating,
encoded on experimental primate studies showing abor-
tificant activity at 2–100 times the corresponding
human dose [12].

By virtue of the first trimester of pregnancy is
characterised by precisely choreographed gene ex-
pression and rapid cell division that lays the founda-
tion for later foetal growth and development [7], it is
completely possible that early IFN exposure may have
affect these early processes to cause later prematurity
and decreased growth.

To the best of our knowledge, there is no embryo
culture study to investigate the teratogenic effects of
IFN\(\beta\)-1a and IFN\(\beta\)-1b on embryos.

<table>
<thead>
<tr>
<th>N</th>
<th>Caudal neural tube</th>
<th>Hindbrain</th>
<th>Midbrain</th>
<th>Forebrain</th>
<th>Olfactory system</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>1000 IU/mL IFN(\beta)-1a</td>
<td>9</td>
<td>7</td>
<td>2</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>1000 IU/mL IFN(\beta)-1b</td>
<td>9</td>
<td>9</td>
<td>3</td>
<td>6</td>
<td>3</td>
</tr>
</tbody>
</table>

N — the number of embryo; Caudal neural tube — 0: Neural layer or neural folds created, 1: Neural layer closed but uncombined with neural fold, 2: Neural folds combined at 4–5 somites
level, 3: Posterior neuropore is shaped but open, 4: A small aperture in the posterior neuropore, 5: Posterior neuropore is closed; Hindbrain — 0: Neural layer was formed, 1: Neural fold is
V-shaped, 2: Neural fold is U-shaped, 3: Anterior neuropore is formed but open, 4: Anterior neuropore is closed, rhombencephalon is shaped, 5: Upper edge of the fourth ventricle and
pons insolated; Midbrain — 0: Mesencephalic brain folds or neural layer formed, 1: Neural fold is V-shaped, 2: Neural fold is U-shaped, 3: Mesencephalic fold partially merged,
4: Mesencephalon is merged, 5: A chamber is formed between the rhinencephalon and the mesencephalon; Forebrain — 0: Neural layer is formed, 1: Neural fold is V-shaped, 2: Neural
fold is U-shaped, 3: Prosencephalic fold partially merged, 4: Prosencephalon is merged, 5: Telencephalic evagination formed; Olfactory system — 0: No symptoms, 1: Olfactory layer is
formed, 2: Olfactory layer is surrounded, 3: Olfactory protrusion is obvious

Table 1. In vitro embryonic development in control and interferon beta (IFN\(\beta\)) groups

<table>
<thead>
<tr>
<th></th>
<th>Control group</th>
<th>1000 IU/mL IFN(\beta)-1a</th>
<th>1000 IU/mL IFN(\beta)-1b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total morphological score</td>
<td>56.25±3.04</td>
<td>56.17±1.32</td>
<td>53.56±2.46</td>
</tr>
<tr>
<td>Somite number</td>
<td>22.2 ± 2.45</td>
<td>21.88 ± 1.13</td>
<td>21.66 ± 0.86</td>
</tr>
<tr>
<td>Yolk sac diameter [mm]</td>
<td>4.79 ± 0.37</td>
<td>4.08 ± 0.32</td>
<td>4.12 ± 0.32</td>
</tr>
<tr>
<td>Crown-rump length [mm]</td>
<td>3.78 ± 0.43</td>
<td>3.34 ± 0.10</td>
<td>3.29 ± 0.19</td>
</tr>
<tr>
<td>Head length [mm]</td>
<td>1.59 ± 0.10</td>
<td>1.44 ± 0.03</td>
<td>1.47 ± 0.04</td>
</tr>
<tr>
<td>Embryo protein content [mg]</td>
<td>187.27±45.77</td>
<td>182.68±7.09</td>
<td>184.83±13.43</td>
</tr>
</tbody>
</table>

*One Way Analysis of Variance (ANOVA) was applied; p < 0.05; SD — standard deviation
In this study, in order to determine the level of development of cultured embryos, total morphological scoring method was used [23]. When developments of embryos were evaluated, no significant differences were detected among the control and experimental groups. On the other hand, when yolk sac diameter, crown rump length and head length were evaluated, significant differences were determined among the control and experimental groups. In the current literature, the yolk sac diameters of control embryos (11.5 days of age) were reported as 3.17 ± 0.14 mm [31], 5.0 ± 0 mm [42], 5.70 ± 0.38 mm, respectively [45]. In this study, yolk sac diameter was calculated as 4.79 ± 0.37 mm in control group and 4.08 ± 0.32 mm, 4.12 ± 0.32 mm in experimental IFNβ-1a and IFNβ-1b groups, respectively. In the current literature, the value of crown-rump lengths were reported to range between 2.80 ± 0.11 and 5.4 ± 0.18 mm in embryos of control groups (11.5 days of age) [31, 42, 45]. In our study, the average crown-rump lengths were determined in the control group as 3.78 ± 0.43 mm, and 3.34 ± 0.10 mm, 3.29 ± 0.19 mm in experimental IFNβ-1a and IFNβ-1b groups, respectively. In another study, mean head length of embryos in the control group was reported as 2.0 mm [36], while in our study, head lengths of the embryos were measured as 1.59 ± 0.10 mm in the control group, 1.44 ± 0.03 mm and 1.47 ± 0.04 mm in experimental IFNβ-1a and IFNβ-1b groups, respectively. As there was no study to use IFN in embryo culture currently, we cannot compare our experimental results. Thus, in our opinion, the decreased results in experimental groups may be the result of IFN use, while the discrepancy of the results of control group may be due to diversity of working environment, the researchers and rat species.

Studies in humans, Amato et al. [2] demonstrated that IFNβ use during pregnancy did not increase the risk of spontaneous miscarriage; however, it was related to low birth weight and short birth length. Boskovic et al. [4] showed that the usage of IFNβ in the first 3 months of pregnancy caused foetal loss and low birth weight when compared to healthy pregnant control group and unexposed pregnant women with MS. On the contrary, Hellwig et al. [17] stated that congenital anomalies were in the normal rate in pregnant women used IFNβ and concluded the drug not to have any teratogenic risk. Sandberg-Wollhem et al. [40] investigated the teratogenic effects of IFNβ-1a on 425 MS patients treated with IFNβ-1a in the process of pregnancy by injection under the skin for at least 45 days. They determined 49 spontaneous abortions, 4 stillbirth and 4 children with congenital anomalies; the incidence of spontaneous abortion and congenital anomalies have been noted within normal range.

In this study, the similarities between the results related to the total morphological score and somites number in all groups demonstrated that mentioned doses of IFNβ-1a and IFNβ-1b had no teratogenic effect on the embryos. Considering this aspect; our results were consistent with Hellwig et al. [17]. However, the significant differences between the control and experimental groups in terms of yolk sac diameter, crown-rump length and head length parameters revealed that embryos growing in IFNβ-1a and IFNβ-1b added medium had lower body size. When evaluated in this respect, our results were consistent with previous studies investigating the relationship between the use of IFNβ and its teratogenicity during pregnancy [2, 4]. They determined that using IFNβ during the first 3 months of pregnancy caused low birth weight and short stature compared to the healthy control group.

In the treatment of MS, the effects of IFNβ-1a and IFNβ-1b on developing embryos during pregnancy are unclear and also being a disease involving the nervous system; in our opinion these drugs can potentially affect the nervous system of embryos, in case of use during pregnancy. IFNs are naturally produced inhibitors of cell growth that can also affect differentiated cell function [38]. IFNs have been previously shown to inhibit the hormone-induced synthesis of several enzymes [3, 19, 32] and the differentiation and proliferation of glial cells [1, 33]. Researchers investigated the effect of IFN-alpha/beta on the expression of glyceral phosphate dehydrogenase (GPDH) in both C6 glioma cells and pure cultures of oligodendrocytes. GPDH is a biochemical marker for oligodendrocytes and is known to be developmentally regulated and steroid inducible. A pre-treatment of these cells with 75 U/mL of IFN-alpha/beta resulted in an inhibition of the hydrocortisone induction of GPDH enzymatic activity by 50% and 40% in C6 cells and oligodendrocytes, respectively. They also found that IFN impaired the accumulation of GPDH mRNA in both cell types. These results demonstrate that IFNs are capable of modifying the cellular response to hormones in cells of neuroepithelial origin, and suggest the possibility that IFNs may be able to influence the development and function of the brain [33]. Thus, embryos cultured
in medium with IFNβ-1a and IFNβ-1b were evaluated in terms of development of the nervous system. We determined numerical redundancy in the embryos of the experimental groups pointing out retardation in the nervous system. Therefore, in our opinion, IFNβ-1a and IFNβ-1b may affect the development of the neural system. The redundancy in the number of the embryos that have poorer neural system development in the experimental groups may be considered in later studies.

Limitations of the study
Our study had some limitations that make it difficult to generalise the results for all of the conditions. The first limitation of our study was the dose of IFNβ; the effect of different doses of IFNβ on embryo development was not investigated in this study. The second limitation was the assessment criteria. We didn’t use histological examination; we evaluated embryonic development by using morphologic score, protein content and morphometric measurements.

CONCLUSIONS
Together with a wide range of other in vitro studies dealing with the teratogenicity of several different molecules, the present findings suggest that the rat post-implantation embryo culture system is a very useful method for teratological studies and also particularly suitable for the assessment of specific effects on morphogenetic events occurring during early organogenesis in mammalian embryos. Consequently, our study demonstrated that 1000 IU/mL IFNβ-1a and 1000 IU/mL IFNβ-1b did not have macroscopic teratogenic effects on the growth of embryos. However, lower values in yolk sac diameter, crown-rump length and head length parameters showed that indicated doses of IFNβ-1a and IFNβ-1b caused growth retardation. As this is the first study using IFNβ in vitro embryo culture technique, the future studies planned with different doses of IFNβ and effects of IFNβ using at different stages of pregnancy will contribute to the literature.

REFERENCES


